Table of Contents Author Guidelines Submit a Manuscript
Cardiovascular Therapeutics
Volume 2019, Article ID 7372129, 10 pages
https://doi.org/10.1155/2019/7372129
Research Article

Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF)

1China-Japan Friendship Hospital, Beijing, China
2Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
3Cardiology Division, Beijing An Zhen Hospital, Capital Medical University, Beijing, China
4Department of Cardiology, Shanghai First People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200080, China
5Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, 116000, China
6Department of Cardiology, Peking University People’s Hospital, Beijing, 100044, China

Correspondence should be addressed to Dayi Hu; moc.621@6102uhiyad

Received 28 September 2018; Revised 7 January 2019; Accepted 18 February 2019; Published 21 March 2019

Academic Editor: James C. Coons

Copyright © 2019 Yihong Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Hu and Y. Sun, “Epidemiology, risk factors for stroke, and management of atrial fibrillation in China,” Journal of the American College of Cardiology, vol. 52, no. 10, pp. 865–868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Oldgren, J. S. Healey, M. Ezekowitz et al., “Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY atrial fibrillation registry,” Circulation, vol. 129, no. 15, pp. 1568–1576, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Y.-J. Shen, J. F. Yao, S. S. Brar, M. B. Jorgensen, and W. Chen, “Racial/Ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation,” Journal of the American College of Cardiology, vol. 50, no. 4, pp. 309–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. Chinese Society of Cardiology, “The anticoagulation in patients with atrial fibrillation: Chinese consensus,” Chinese Journal of Internal Medicine, vol. 51, no. 11, pp. 916–921, 2012. View at Google Scholar
  5. A. J. Camm, P. Kirchhof, G. Y. Lip et al., “Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC),” European Heart Journal, vol. 31, no. 19, pp. 2369–2429, 2010. View at Google Scholar · View at Scopus
  6. Y. Guo, S. Apostolakis, A. D. Blann et al., “Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation,” International Journal of Cardiology, vol. 168, no. 2, pp. 904–909, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. T.-F. Chao, C.-J. Liu, T.-C. Tuan et al., “Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians?” Heart Rhythm, vol. 13, no. 1, pp. 46–53, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. C. T. January, L. S. Wann, H. Calkins et al., “2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of Cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society,” Journal of the American College of Cardiology, 2019. View at Google Scholar
  9. A. K. Kakkar, I. Mueller, J. Bassand et al., “Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry,” PLoS ONE, vol. 8, no. 5, article e63479, 2013. View at Publisher · View at Google Scholar
  10. R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De Vos, H. J. G. M. Crijns, and G. Y. H. Lip, “A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey,” CHEST, vol. 138, no. 5, pp. 1093–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. E. J. Choi, I.-H. Lee, and N. K. Je, “Inadequate stroke prevention in Korean atrial fibrillation patients in the post-warfarin era,” International Journal of Cardiology, vol. 220, pp. 647–652, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Kannel, P. Wolf, E. Benjamin, and D. Levy, “Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates,” American Journal of Cardiology, vol. 82, no. 8A, pp. 2N–9N, 1998. View at Publisher · View at Google Scholar
  13. B. Gorenek, A. Pelliccia, E. J. Benjamin et al., “European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS),” Europace, vol. 19, no. 2, pp. 190–225, 2017. View at Google Scholar · View at Scopus
  14. “Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials,” Archives of Internal Medicine, vol. 154, no. 13, pp. 1449–1457, 1994.
  15. Stroke Risk in Atrial Fibrillation Working, “Independent predictors of stroke in patients with atrial fibrillation: a systematic review,” Neurology, vol. 69, no. 6, pp. 546–554, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Vemulapalli, A. S. Hellkamp, W. S. Jones et al., “Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the ROCKET AF Trial,” American Heart Journal, vol. 178, pp. 74–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Kim, P.-S. Yang, T.-H. Kim et al., “Ideal blood pressure in patients with atrial fibrillation,” Journal of the American College of Cardiology, vol. 72, no. 11, pp. 1233–1245, 2018. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Liu, B. Wu, W. Wang, L. Lee, S. Zhang, and L. Kong, “Stroke in China: epidemiology, prevention, and management strategies,” The Lancet Neurology, vol. 6, no. 5, pp. 456–464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S.-S. Chang, J.-Z. Dong, C.-S. Ma et al., “Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: the Chinese atrial fibrillation registry study,” Stroke, vol. 47, no. 7, pp. 1803–1810, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. J. C. Hsu, P. S. Chan, F. Tang, T. M. Maddox, and G. M. Marcus, “Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation,” American Journal of Medicine, vol. 128, no. 6, pp. 654.e1–654.e10, 2015. View at Publisher · View at Google Scholar
  21. A. N. Ganesan, D. P. Chew, T. Hartshorne et al., “The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis,” European Heart Journal, vol. 37, no. 20, pp. 1591–1602, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Boriani, C. Laroche, I. Diemberger et al., “'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) general pilot registry,” Europace, vol. 18, no. 5, pp. 648–657, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Vanassche, M. N. Lauw, J. W. Eikelboom et al., “Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in active-a and averroes,” European Heart Journal, vol. 36, no. 5, pp. 281–287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Y. H. Lip, K. Huber, F. Andreotti et al., “Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting,” Thrombosis and Haemostasis, vol. 103, no. 1, pp. 13–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. L. Fosbol, T. Y. Wang, S. Li et al., “Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction,” American Heart Journal, vol. 163, no. 4, pp. 720–728, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Lamberts, G. H. Gislason, J. B. Olesen et al., “Oral Anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention,” Journal of the American College of Cardiology, vol. 62, no. 11, pp. 981–989, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Y. H. Lip, J. P. Collet, M. Haude, and K. Huber, “Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA),” European Heart Journal, vol. 39, no. 31, pp. 2847–2850, 2018. View at Google Scholar · View at Scopus
  28. M. R. Reynolds, T. Lavelle, V. Essebag, D. J. Cohen, and P. Zimetbaum, “Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study,” American Heart Journal, vol. 152, no. 6, pp. 1097–1103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. V. Freeman, D. N. Simon, A. S. Go et al., “Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF),” Circulation: Cardiovascular Quality and Outcomes, vol. 8, no. 4, pp. 393–402, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. B. U. Monz, S. J. Connolly, M. Korhonen, H. Noack, and J. Pooley, “Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study,” International Journal of Cardiology, vol. 168, no. 3, pp. 2540–2547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. Y.-H. Chan, K.-C. Yen, L.-C. See et al., “Cardiovascular, bleeding, and mortality risks of dabigatran in asians with nonvalvular atrial fibrillation,” Stroke, vol. 47, no. 2, pp. 441–449, 2016. View at Publisher · View at Google Scholar · View at Scopus